Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol

Kadoaki Oohashi, Katsuyuki Hotta, Taizo Hirata, Keisuke Aoe, Toshiyuki Kozuki, Kiichiro Ninomiya, Hiroe Kayatani, Hiroyuki Yanai, Shinichi Toyooka, Shiro Hinotsu, Minoru Takata, Katsuyuki Kiura

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The treatment outcome has been unsatisfactory for patients with non–small-cell lung cancer (NSCLC) refractory to standard first-line chemotherapy. Trastuzumab emtansine (T-DM1), an anti-HER2 antibody conjugated with a vinca alkaloid, has been approved for clinical use in HER2+ breast cancer in many countries. Approximately 5% of NSCLC tumors possess HER2 alterations, and T-DM1 has shown excellent antitumor effects against HER2+ lung cancer cell lines in preclinical models. Therefore, we hypothesized that T-DM1 could significantly inhibit the growth of HER2+ lung cancers. We have launched a nonrandomized phase II trial of T-DM1 monotherapy for patients with HER2+ lung cancers. The major eligibility criteria are as follows: age ≥ 20 years, pathologically diagnosed NSCLC with documented HER2 positivity (immunohistochemistry 3+, both immunohistochemistry 2+ and fluorescence in situ hybridization positive, or exon 20 insertion mutation), and previous chemotherapy. Thirty patients will receive T-DM1 3.6 mg/kg every 3 weeks. The primary endpoint is the overall response rate. This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.

Original languageEnglish
Pages (from-to)92-95
Number of pages4
JournalClinical Lung Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Immunohistochemistry
Vinca Alkaloids
Drug Therapy
Insertional Mutagenesis
Fluorescence In Situ Hybridization
Anti-Idiotypic Antibodies
Exons
Breast Neoplasms
Cell Line
ado-trastuzumab emtansine
Growth
Neoplasms

Keywords

  • HER2 amplification
  • HER2 mutations
  • HER2 over-expression
  • NSCLC
  • Trastuzumab emtansine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer : Study Protocol. / Oohashi, Kadoaki; Hotta, Katsuyuki; Hirata, Taizo; Aoe, Keisuke; Kozuki, Toshiyuki; Ninomiya, Kiichiro; Kayatani, Hiroe; Yanai, Hiroyuki; Toyooka, Shinichi; Hinotsu, Shiro; Takata, Minoru; Kiura, Katsuyuki.

In: Clinical Lung Cancer, Vol. 18, No. 1, 01.01.2017, p. 92-95.

Research output: Contribution to journalArticle

@article{1b0c0a5d12b14afaa7a32abc413654f5,
title = "Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol",
abstract = "The treatment outcome has been unsatisfactory for patients with non–small-cell lung cancer (NSCLC) refractory to standard first-line chemotherapy. Trastuzumab emtansine (T-DM1), an anti-HER2 antibody conjugated with a vinca alkaloid, has been approved for clinical use in HER2+ breast cancer in many countries. Approximately 5{\%} of NSCLC tumors possess HER2 alterations, and T-DM1 has shown excellent antitumor effects against HER2+ lung cancer cell lines in preclinical models. Therefore, we hypothesized that T-DM1 could significantly inhibit the growth of HER2+ lung cancers. We have launched a nonrandomized phase II trial of T-DM1 monotherapy for patients with HER2+ lung cancers. The major eligibility criteria are as follows: age ≥ 20 years, pathologically diagnosed NSCLC with documented HER2 positivity (immunohistochemistry 3+, both immunohistochemistry 2+ and fluorescence in situ hybridization positive, or exon 20 insertion mutation), and previous chemotherapy. Thirty patients will receive T-DM1 3.6 mg/kg every 3 weeks. The primary endpoint is the overall response rate. This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.",
keywords = "HER2 amplification, HER2 mutations, HER2 over-expression, NSCLC, Trastuzumab emtansine",
author = "Kadoaki Oohashi and Katsuyuki Hotta and Taizo Hirata and Keisuke Aoe and Toshiyuki Kozuki and Kiichiro Ninomiya and Hiroe Kayatani and Hiroyuki Yanai and Shinichi Toyooka and Shiro Hinotsu and Minoru Takata and Katsuyuki Kiura",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2016.06.014",
language = "English",
volume = "18",
pages = "92--95",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer

T2 - Study Protocol

AU - Oohashi, Kadoaki

AU - Hotta, Katsuyuki

AU - Hirata, Taizo

AU - Aoe, Keisuke

AU - Kozuki, Toshiyuki

AU - Ninomiya, Kiichiro

AU - Kayatani, Hiroe

AU - Yanai, Hiroyuki

AU - Toyooka, Shinichi

AU - Hinotsu, Shiro

AU - Takata, Minoru

AU - Kiura, Katsuyuki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The treatment outcome has been unsatisfactory for patients with non–small-cell lung cancer (NSCLC) refractory to standard first-line chemotherapy. Trastuzumab emtansine (T-DM1), an anti-HER2 antibody conjugated with a vinca alkaloid, has been approved for clinical use in HER2+ breast cancer in many countries. Approximately 5% of NSCLC tumors possess HER2 alterations, and T-DM1 has shown excellent antitumor effects against HER2+ lung cancer cell lines in preclinical models. Therefore, we hypothesized that T-DM1 could significantly inhibit the growth of HER2+ lung cancers. We have launched a nonrandomized phase II trial of T-DM1 monotherapy for patients with HER2+ lung cancers. The major eligibility criteria are as follows: age ≥ 20 years, pathologically diagnosed NSCLC with documented HER2 positivity (immunohistochemistry 3+, both immunohistochemistry 2+ and fluorescence in situ hybridization positive, or exon 20 insertion mutation), and previous chemotherapy. Thirty patients will receive T-DM1 3.6 mg/kg every 3 weeks. The primary endpoint is the overall response rate. This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.

AB - The treatment outcome has been unsatisfactory for patients with non–small-cell lung cancer (NSCLC) refractory to standard first-line chemotherapy. Trastuzumab emtansine (T-DM1), an anti-HER2 antibody conjugated with a vinca alkaloid, has been approved for clinical use in HER2+ breast cancer in many countries. Approximately 5% of NSCLC tumors possess HER2 alterations, and T-DM1 has shown excellent antitumor effects against HER2+ lung cancer cell lines in preclinical models. Therefore, we hypothesized that T-DM1 could significantly inhibit the growth of HER2+ lung cancers. We have launched a nonrandomized phase II trial of T-DM1 monotherapy for patients with HER2+ lung cancers. The major eligibility criteria are as follows: age ≥ 20 years, pathologically diagnosed NSCLC with documented HER2 positivity (immunohistochemistry 3+, both immunohistochemistry 2+ and fluorescence in situ hybridization positive, or exon 20 insertion mutation), and previous chemotherapy. Thirty patients will receive T-DM1 3.6 mg/kg every 3 weeks. The primary endpoint is the overall response rate. This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.

KW - HER2 amplification

KW - HER2 mutations

KW - HER2 over-expression

KW - NSCLC

KW - Trastuzumab emtansine

UR - http://www.scopus.com/inward/record.url?scp=84998537702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998537702&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.06.014

DO - 10.1016/j.cllc.2016.06.014

M3 - Article

C2 - 27497829

AN - SCOPUS:84998537702

VL - 18

SP - 92

EP - 95

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -